SELUTION SLR DEB: A Major Breakthrough for Coronary ISR

The US Food and Drug Administration has approved the SELUTION SLR DEB for coronary in-stent restenosis. Consequently, interventional cardiologists now have access to the first sirolimus-eluting balloon cleared in the United States. This milestone marks a critical shift toward stentless cardiovascular interventions. Furthermore, the device delivers therapeutic drug levels without leaving a permanent metallic scaffold inside the vessel.

Clinical Evidence Behind SELUTION SLR DEB

The regulatory clearance rests upon robust data from the randomized SELUTION4ISR clinical study. Specifically, investigators evaluated over 400 patients across 48 global sites. The trial compared this novel technology against the blended standard of care, primarily repeat drug-eluting stents. Ultimately, the study met its primary non-inferiority endpoint for target lesion failure at 12 months. In addition, the platform boasts clinical evidence covering more than 5,000 patients globally.

Addressing Coronary In-Stent Restenosis

Coronary in-stent restenosis accounts for roughly 10% of percutaneous coronary interventions. Previously, American operators relied solely on paclitaxel-coated balloons or repeat stenting. However, adding multiple metallic stent layers increases the risk of recurrent restenosis and thrombosis. Therefore, a sirolimus-based balloon offers a safer antiproliferative profile for complex cath lab cases. The balloon utilizes proprietary micro-reservoirs to sustain sirolimus release for 90 days.

Global Innovation and Indian Leadership

MedAlliance co-founder Amit Bohora spearheaded the initial development and regulatory expansion of this platform. Moreover, Dr. Praveen Chandra from India served as the principal investigator for the first-in-human trial. Cordis later acquired MedAlliance in a landmark transaction valued at 1.135 billion dollars. As a result, this approval highlights how global collaboration and Indian clinical leadership reshape cardiovascular care. Currently, Cordis is also completing trials evaluating the balloon for de novo small vessel disease.

Frequently Asked Questions

Q1: What is the SELUTION SLR DEB?

The SELUTION SLR DEB is a coronary drug-eluting balloon that delivers sirolimus to prevent restenosis without permanent implants.

Q2: Why is sirolimus preferred for in-stent restenosis?

Sirolimus provides strong cytostatic tissue inhibition with a wide therapeutic window and lower inflammatory risk than paclitaxel.

Q3: Which clinical trial supported this FDA approval?

The FDA based its approval on the SELUTION4ISR trial, which demonstrated non-inferiority against standard treatments at one year.

References

1. SELUTION SLR™ DEB Wins US FDA Approval for In-Stent Restenosis -Cofounder AmitBohora Calls It A Defining Milestone for Stentless CardiacCare - ETHealthworld
2. Cutlip DE, Mehran R, Doros G, et al. Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design. American Heart Journal. 2025;284:11-19.
3. Cordis Corporation. SELUTION SLR PTCA Drug-Eluting Balloon Receives US FDA Approval for Coronary In-Stent Restenosis. Press Release; September 2026.
4. Cardiovascular Research Foundation. Novel Sirolimus-Eluting Balloon Appears Noninferior to Conventional Therapies for Treatment of In-stent Restenosis: SELUTION4ISR Results. TCT 2025.